Intarcia Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Intarcia Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013971
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:46
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Intarcia Therapeutics Inc (Intarcia), formerly BioMedicines Inc, is a biopharmaceutical company that discovers, develops and commercializes drug therapies and reduces effects for chronic diseases. The company’s product candidate include ITCA 650 is in Phase III clinical trial. Its ITCA 650 is used for the treatment of type II diabetes and obesity. Intarcia offers technology platform delivery feasibility testing that helps to develop proprietary formulations and evaluation of drug candidates the formulations. The company uses medical drug delivery system, a proprietary technology platform to develop the drugs. It operates through its manufacturing facility in Hayward, California. Intarcia is headquartered in Boston, Massachusetts, the US.

Intarcia Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Intarcia Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Intarcia Therapeutics Raises USD75 Million in Financing 13
Phoundry Pharma Raises USD0.5 Million in Seed Financing 14
Intarcia Therapeutics Raises US$200 Million In Venture Financing 15
Intarcia Therapeutics Raises US$210 Million In Venture Financing 17
Intarcia Therapeutics Raises Additional US$5.5 Million In Venture financing 19
Intarcia Therapeutics Raises US$7.3 Million In Venture financing 20
Intarcia Therapeutics Secures US$13.28 Million In Third Tranche Of Venture Financing Round 22
Partnerships 23
Intarcia Therapeutics Enters into Co-Development Agreement with Numab 23
Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 24
Intarcia Therapeutics Enters Into Co-Development Agreement With Quintiles For ITCA 650 25
Licensing Agreements 27
Intarcia Therapeutics Enters into Licensing Agreement with California Institute for Biomedical Research 27
Intarcia Therapeutics Plans To License Drug-Formulation Technology 28
Equity Offering 29
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 29
Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares 30
Debt Offering 31
Intarcia Therapeutics Raises USD300 Million in Financing 31
Acquisition 32
Intarcia Therapeutics Acquires Phoundry Pharma 32
Intarcia Therapeutics Inc – Key Competitors 33
Intarcia Therapeutics Inc – Key Employees 34
Intarcia Therapeutics Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Government and Public Interest 36
Jun 12, 2016: New NHANES Analysis Shows No Improvement in Last Decade to Get More Diabetes Patients to HbA1c Goal 36
Product News 38
09/15/2017: New Intarcia Study Evaluates Optimal Way to Switch from Daily Liraglutide Injections to ITCA 650 in Patients with Type 2 Diabetes 38
06/02/2016: Intarcia and Numab Announce Achievement of Key Research and Development Milestones 39
Product Approvals 40
Feb 03, 2017: Intarcia Announces FDA Filing Acceptance of New Drug Application (NDA) for ITCA 650 for the Treatment of Type 2 Diabetes 40
Nov 21, 2016: Intarcia Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of ITCA 650 in Type 2 Diabetes 41
Clinical Trials 42
Jun 12, 2016: Intarcia Presents FREEDOM-2 Trial Results in Type 2 Diabetes Demonstrating Clinically Meaningful Superiority and Sustained Glucose Control and Weight Reduction for ITCA 650 vs. Januvia: Oral Presentation at ADA 76th Scientific Sessions 42
May 06, 2016: Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes 44
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Intarcia Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Intarcia Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10
Intarcia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Intarcia Therapeutics Raises USD75 Million in Financing 13
Phoundry Pharma Raises USD0.5 Million in Seed Financing 14
Intarcia Therapeutics Raises US$200 Million In Venture Financing 15
Intarcia Therapeutics Raises US$210 Million In Venture Financing 17
Intarcia Therapeutics Raises Additional US$5.5 Million In Venture financing 19
Intarcia Therapeutics Raises US$7.3 Million In Venture financing 20
Intarcia Therapeutics Secures US$13.28 Million In Third Tranche Of Venture Financing Round 22
Intarcia Therapeutics Enters into Co-Development Agreement with Numab 23
Intarcia Therapeutics Enters into Co-Development Agreement with Servier for ITCA 650 24
Intarcia Therapeutics Enters Into Co-Development Agreement With Quintiles For ITCA 650 25
Intarcia Therapeutics Enters into Licensing Agreement with California Institute for Biomedical Research 27
Intarcia Therapeutics Plans To License Drug-Formulation Technology 28
Intarcia Therapeutics Raises USD206 Million in Second Tranche of Private Placement of Shares 29
Intarcia Therapeutics Raises USD215 Million in First Tranche of Private Placement of Shares 30
Intarcia Therapeutics Raises USD300 Million in Financing 31
Intarcia Therapeutics Acquires Phoundry Pharma 32
Intarcia Therapeutics Inc, Key Competitors 33
Intarcia Therapeutics Inc, Key Employees 34
Intarcia Therapeutics Inc, Other Locations 35
Intarcia Therapeutics Inc, Subsidiaries 35

★海外企業調査レポート[Intarcia Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hon Hai Precision Industry Co., Ltd.:企業の戦略・SWOT・財務情報
    Hon Hai Precision Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hon Hai Precision Industry Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • HDR Inc:企業の戦略的SWOT分析
    HDR Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • China Gezhouba Group Co Ltd (600068):企業の財務・戦略的SWOT分析
    China Gezhouba Group Co Ltd (600068) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ben E. Keith Company:戦略・SWOT・企業財務分析
    Ben E. Keith Company - Strategy, SWOT and Corporate Finance Report Summary Ben E. Keith Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Eni SpA Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Eni SpA Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Eni SpA (Eni) is an integrated oil and gas company. The company carries out oil and natural gas exploration, field development and production activities. It also involved in supply, trading and shipping of n …
  • Oklahoma Medical Research Foundation:製薬・医療:M&Aディール及び事業提携情報
    Summary Oklahoma Medical Research Foundation (OMRF) is a non-profit biomedical research institute. The institute conducts disease research for human diseases such as lupus, alzheimer’s and diseases of aging, diabetics, cancer, children’s disease, autoimmune disease and heart diseases. Its portfolio …
  • Riken Vitamin Co Ltd:企業の戦略・SWOT・財務情報
    Riken Vitamin Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Riken Vitamin Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Thermax Ltd (THERMAX):企業の財務・戦略的SWOT分析
    Thermax Ltd (THERMAX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Koito Manufacturing Co Ltd:企業の戦略・SWOT・財務情報
    Koito Manufacturing Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Koito Manufacturing Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Levi Strauss & Co (LEVI):企業の財務・戦略的SWOT分析
    Levi Strauss & Co (LEVI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • University of Glasgow-製薬・医療分野:企業M&A・提携分析
    Summary University of Glasgow (UOG) is an educational and research institute that offers undergraduate, post graduate, and online programs. The institute operates through its departments for law, medicine, veterinary medicine and dentistry. It offers courses across various disciplines that include a …
  • BioPorto Diagnostics AS:医療機器:M&Aディール及び事業提携情報
    Summary BioPorto Diagnostics AS (BioPorto Diagnostics), formerly AntibodyShop AS is an in-vitro diagnostics company that manufactures and markets antibodies and antibody based products. The company’s products include matched reagent set, immunoassays, antigens, antibodies, controls calibrators and m …
  • Imbed Biosciences Inc-医療機器分野:企業M&A・提携分析
    Summary Imbed Biosciences Inc (Imbed) is a medical device company which develops technologies for the management of burns, chronic ulcers, gastro-intestinal defects, and tissue repair. The company’s product platform, a polymeric Microfilm develops bioactive molecules on tissue surfaces to manage wou …
  • British American Tobacco (Malaysia) Berhad:戦略・SWOT・企業財務分析
    British American Tobacco (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report Summary British American Tobacco (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • Ko Yo Chemical (Group) Ltd (827):企業の財務・戦略的SWOT分析
    Ko Yo Chemical (Group) Ltd (827) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Safran SA (SAF):企業の財務・戦略的SWOT分析
    Safran SA (SAF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • NGK Insulators, Ltd.:企業の戦略・SWOT・財務分析
    NGK Insulators, Ltd. - Strategy, SWOT and Corporate Finance Report Summary NGK Insulators, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Constantia Industries AG:企業の戦略的SWOT分析
    Constantia Industries AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Severn Glocon Group Plc:石油・ガス:M&Aディール及び事業提携情報
    Summary Severn Glocon Group Plc (Severn Glocon), formerly Sageshire Ltd is a designer and manufacturer of engineered valve products. The company offers control, choke, and subsea valves; small bore subsea valves and actuators; filters and dryers; low-friction valve actuators, engineered valves, meta …
  • SMART Medical Systems Ltd-医療機器分野:企業M&A・提携分析
    Summary Smart Medical Systems Ltd (Smart) is a medical device company that develops and manufactures medical equipment in the field of gastroenterology and GI endoscopy. The company offers products such as inflation systems, platform, naviaid ABC, G-eye, naviaid AB, future naviaid products, controll …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆